[Treatment of acute myocardial infarction--an elucidative report]. 1989

E B Madsen, and J Godtfredsen, and J F Hansen, and G Jensen, and B L Nielsen, and P E Nielsen, and T T Nielsen, and A Pedersen, and F Rømer, and E Sandøe

The present-day optimal treatment of patients with acute myocardial infarction (AMI) is reviewed. The prehospital phase should be as brief as possible. Emergency observation and treatment in hospital should be initiated without delay. Schematic stages for mobilization have been discarded and free mobilization is recommended. Routine acute intervention with thrombolysis is recommended for patients in whom symptoms have been present for 6-12 hours and treatment with Aspirin is recommended. Beta-blocking agents are recommended for patients with increased risk after discharge. Treatment of ventricular and supraventricular arrhythmias, block and cardiac failure are reviewed in detail. Patients without complications should be monitored for three to five days and may be discharged after seven to ten days. Exercise ECG should be carried out at discharge to assess the working capacity, ischaemia and subjective reaction. The importance of good patient information is emphasized. Cessation of smoking, control of lipids and blood pressure are important as secondary interventions. As far as possible, outpatient control should be offered after discharge. The criteria for referral to specialized cardiological departments are established both for emergency and elective referral. Patients under the age of 70 years with high risk for repeated AMI or death after discharge (with residual ischaemia) should possibly be referred for coronary arteriography.

UI MeSH Term Description Entries
D007902 Length of Stay The period of confinement of a patient to a hospital or other health facility. Hospital Stay,Hospital Stays,Stay Length,Stay Lengths,Stay, Hospital,Stays, Hospital
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010353 Patient Education as Topic The teaching or training of patients concerning their own health needs. Education of Patients,Education, Patient,Patient Education
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

E B Madsen, and J Godtfredsen, and J F Hansen, and G Jensen, and B L Nielsen, and P E Nielsen, and T T Nielsen, and A Pedersen, and F Rømer, and E Sandøe
January 1970, Advances in cardiology,
E B Madsen, and J Godtfredsen, and J F Hansen, and G Jensen, and B L Nielsen, and P E Nielsen, and T T Nielsen, and A Pedersen, and F Rømer, and E Sandøe
January 1988, Practica odontologica,
E B Madsen, and J Godtfredsen, and J F Hansen, and G Jensen, and B L Nielsen, and P E Nielsen, and T T Nielsen, and A Pedersen, and F Rømer, and E Sandøe
July 2005, American journal of critical care : an official publication, American Association of Critical-Care Nurses,
E B Madsen, and J Godtfredsen, and J F Hansen, and G Jensen, and B L Nielsen, and P E Nielsen, and T T Nielsen, and A Pedersen, and F Rømer, and E Sandøe
March 2008, Herz,
E B Madsen, and J Godtfredsen, and J F Hansen, and G Jensen, and B L Nielsen, and P E Nielsen, and T T Nielsen, and A Pedersen, and F Rømer, and E Sandøe
August 1993, The New England journal of medicine,
E B Madsen, and J Godtfredsen, and J F Hansen, and G Jensen, and B L Nielsen, and P E Nielsen, and T T Nielsen, and A Pedersen, and F Rømer, and E Sandøe
September 2001, Journal of public health medicine,
E B Madsen, and J Godtfredsen, and J F Hansen, and G Jensen, and B L Nielsen, and P E Nielsen, and T T Nielsen, and A Pedersen, and F Rømer, and E Sandøe
January 2001, The American journal of geriatric cardiology,
E B Madsen, and J Godtfredsen, and J F Hansen, and G Jensen, and B L Nielsen, and P E Nielsen, and T T Nielsen, and A Pedersen, and F Rømer, and E Sandøe
August 1993, The New England journal of medicine,
E B Madsen, and J Godtfredsen, and J F Hansen, and G Jensen, and B L Nielsen, and P E Nielsen, and T T Nielsen, and A Pedersen, and F Rømer, and E Sandøe
August 1993, The New England journal of medicine,
E B Madsen, and J Godtfredsen, and J F Hansen, and G Jensen, and B L Nielsen, and P E Nielsen, and T T Nielsen, and A Pedersen, and F Rømer, and E Sandøe
August 1993, The New England journal of medicine,
Copied contents to your clipboard!